CIK 0001372299 · Non-accelerated filer<br>Smaller reporting company
Ocugen, Inc.
Sign in to watch- Ticker
- OCGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 484-328-4701
- Business address
- 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355
- Former names
- HISTOGENICS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,088,801
- in 2 filings, $1.1M under 10b5-1 plans
Net −$1,088,801. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-09 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 | −468,727 | $0.95 | $445K | 4,018,470 |
| 2026-10-09 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 | −57,264 | $0.95 | $54K | 1,030,771 |
| 2026-09-09 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 | −468,727 | $1.12 | $525K | 4,487,197 |
| 2026-09-09 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 | −57,264 | $1.12 | $64K | 1,088,035 |
| 2026-06-15 | Johnson-Greene Treerita Essalima Chief Financial Officer | Purchase | +21,000 | $1.23 | $26K | 521,000 |
| 2026-06-11 | Kompella Uday Director | Grant or award · Stock Option (Right to Buy) | +170,100 | 170,100 | ||
| 2026-06-11 | Chandrasekhar Satishchandran Director | Grant or award · Stock Option (Right to Buy) | +170,100 | 170,100 | ||
| 2026-06-11 | Castillo Kirsten Director | Grant or award · Stock Option (Right to Buy) | +170,100 | 170,100 | ||
| 2026-06-11 | Zhang Junge Director | Grant or award · Stock Option (Right to Buy) | +170,100 | 170,100 | ||
| 2026-06-11 | Coleman Blaise Director | Grant or award · Stock Option (Right to Buy) | +170,100 | 170,100 | ||
| 2026-04-01 | Zhang Junge Director | Option exercise | +15,000 | $0.51 | $8K | 1,180,182 |
| 2026-04-01 | Zhang Junge Director | Option exercise | +112,205 | $0.46 | $52K | 1,292,387 |
| 2026-04-01 | Zhang Junge Director | Option exercise | +66,929 | $1.42 | $95K | 1,359,316 |
| 2026-04-01 | Zhang Junge Director | Option exercise · Option (right to buy) | −15,000 | 0 | ||
| 2026-04-01 | Zhang Junge Director | Option exercise · Option (right to buy) | −112,205 | 0 | ||
| 2026-04-01 | Zhang Junge Director | Option exercise · Option (right to buy) | −66,929 | 0 | ||
| 2026-01-02 | Musunuri Shankar Chief Executive Officer | Grant or award | +3,123,201 | 4,955,924 | ||
| 2026-01-02 | Musunuri Shankar Chief Executive Officer | Grant or award · Option (Right to Buy) | +3,123,201 | 3,123,201 | ||
| 2026-01-02 | Ramachandran Ramesh Chief Accounting Officer | Grant or award | +207,300 | 209,100 | ||
| 2026-01-02 | Ramachandran Ramesh Chief Accounting Officer | Grant or award · Option (Right to Buy) | +310,950 | 310,950 |
Page 1 of 27 · 525 trades